NCT05377216 Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation
| NCT ID | NCT05377216 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | University of Pennsylvania |
| Condition | Ventricular Tachycardia |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2022-09-01 |
| Primary Completion | 2027-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 20 participants in total. It began in 2022-09-01 with a primary completion date of 2027-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Prospective cohort study evaluating the electrophysiologic and biochemical effects of stellate ganglion block in patients with ventricular tachycardia.
Eligibility Criteria
Inclusion Criteria: * Planned catheter based VT ablation * Age at least 18 years Exclusion Criteria: * Pregnancy * Contraindication to SGB or VT ablation * Hypersensitivity of local anesthetic of amide type * Hemodynamic instability during the procedure prior to the study protocol
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05377216 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ventricular Tachycardia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05377216 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05377216 currently recruiting?
Yes, NCT05377216 is actively recruiting participants. Contact the research team at timothy.markman@pennmedicine.upenn.edu for enrollment information.
Where is the NCT05377216 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT05377216 clinical trial?
NCT05377216 is sponsored by University of Pennsylvania. The trial plans to enroll 20 participants.